Suspension of trading

NeuBase Therapeutics, Inc. Stock Nasdaq

NBSE

US64132K2015

Biotechnology & Medical Research

Market Closed - Nasdaq 00:30:00 11/05/2024 +04			5-day change	1st Jan Change
0.3780 ^USD	-3.20%		-.--%	-

08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI

Valuation: NeuBase Therapeutics, Inc.

Market Cap	1.28M 1.11M 1.05M 955K 1.79M 123M 1.8M 12.6M 4.86M 62.34M 4.8M 4.69M 201M	P/E 2023 *	-	P/E 2024 *	-
Enterprise Value	1.28M 1.11M 1.05M 955K 1.79M 123M 1.8M 12.6M 4.86M 62.34M 4.8M 4.69M 201M	EV / Sales 2023 *	-	EV / Sales 2024 *	-
Free-Float	86.62%	Yield 2023 *	-	Yield 2024 *	-

* Estimated data More valuation ratios

Latest news: NeuBase Therapeutics, Inc.

08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Chief Financial Officer	CI
08/01/25	Neubase Therapeutics, Inc. Announces Resignation of Todd P. Branning as Interim Chief Executive Officer	CI
28/06/24	NeuBase Therapeutics, Inc. Announces Board Resignations	CI
29/05/24	NeuBase Therapeutics, Inc. announced that it has received $0.000001 million in funding	CI

More news

Managers and Directors: NeuBase Therapeutics, Inc.

Manager	Title	Age	Since
Ron Sarkar PRN	Corporate Officer/Principal	-	01/11/2021

Director	Title	Age	Since
Todd Branning BRD	Director/Board Member	56	04/01/2025

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEUBASE THERAPEUTICS, INC.	-3.20%	-.--%	-	-	1.39M
LONZA GROUP AG	+0.11%	+2.71%	+0.44%	+26.85%	46.28B
IQVIA HOLDINGS INC.	-1.12%	+1.78%	+42.30%	+27.55%	43.85B
REVOLUTION MEDICINES, INC.	-3.04%	-6.29%	+338.56%	+515.97%	40.93B
BEONE MEDICINES AG	-0.74%	+1.25%	+4.92%	+67.98%	39.89B
CELLTRION, INC.	-0.50%	+0.67%	+10.29%	+41.28%	29.5B
MEDPACE HOLDINGS, INC.	-0.46%	+4.22%	+22.81%	+139.44%	17.09B
ASCENDIS PHARMA A/S	-0.97%	-10.17%	-	-	15.55B
EUROFINS SCIENTIFIC SE	-0.57%	+8.12%	+22.19%	+38.68%	15.22B
TEMPUS AI, INC.	-3.14%	+31.91%	-11.79%	-	14.05B
Average	-1.36%	+3.76%	+53.72%	+122.54%	29.15B
Weighted average by Cap.	-1.10%	+1.87%	+68.04%	+130.90%

See all sector performances

NeuBase Therapeutics, Inc. is a United States-based preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Companyâ€™s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntingtonâ€™s disease (HD), and oncology and in gene editing applications.

Employees

Sector

Biotechnology & Medical Research

More about the company